CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB (CEVI) - Total Assets
Latest total assets as of December 2025: Skr1.09 Billion SEK
Based on the latest financial reports, CellaVision AB (CEVI) holds total assets worth Skr1.09 Billion SEK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CellaVision AB - Total Assets Trend (2000–2025)
This chart illustrates how CellaVision AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CellaVision AB - Asset Composition Analysis
Current Asset Composition (December 2025)
CellaVision AB's total assets of Skr1.09 Billion consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 17.2% |
| Accounts Receivable | Skr141.07 Million | 12.9% |
| Inventory | Skr111.81 Million | 10.2% |
| Property, Plant & Equipment | Skr122.37 Million | 11.2% |
| Intangible Assets | Skr408.20 Million | 37.3% |
| Goodwill | Skr120.68 Million | 11.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how CellaVision AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CellaVision AB's current assets represent 40.3% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2025, down from 71.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 37.3% of total assets.
CellaVision AB Competitors by Total Assets
Key competitors of CellaVision AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
CellaVision AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - CellaVision AB generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, CellaVision AB generates $ 13.98 in net profit.
CellaVision AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.98 | 3.72 | 2.87 |
| Quick Ratio | 2.97 | 2.56 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr330.17 Million | Skr 293.70 Million | Skr 213.17 Million |
CellaVision AB - Advanced Valuation Insights
This section examines the relationship between CellaVision AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.01 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | Skr1.09 Billion |
| Market Capitalization | $262.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values CellaVision AB's assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CellaVision AB's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CellaVision AB (2000–2025)
The table below shows the annual total assets of CellaVision AB from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.09 Billion | +8.20% |
| 2024-12-31 | Skr1.01 Billion | +8.96% |
| 2023-12-31 | Skr928.71 Million | +4.15% |
| 2022-12-31 | Skr891.75 Million | +8.06% |
| 2021-12-31 | Skr825.21 Million | +23.53% |
| 2020-12-31 | Skr668.02 Million | +4.10% |
| 2019-12-31 | Skr641.71 Million | +72.14% |
| 2018-12-31 | Skr372.78 Million | +24.01% |
| 2017-12-31 | Skr300.60 Million | +17.22% |
| 2016-12-31 | Skr256.44 Million | +16.34% |
| 2015-12-31 | Skr220.43 Million | +8.99% |
| 2014-12-31 | Skr202.25 Million | +7.25% |
| 2013-12-31 | Skr188.57 Million | +5.61% |
| 2012-12-31 | Skr178.56 Million | -0.10% |
| 2011-12-31 | Skr178.73 Million | +9.99% |
| 2010-12-31 | Skr162.50 Million | +43.36% |
| 2009-12-31 | Skr113.35 Million | +17.50% |
| 2008-12-31 | Skr96.47 Million | +118.66% |
| 2007-12-31 | Skr44.12 Million | +6.75% |
| 2006-12-31 | Skr41.33 Million | -10.62% |
| 2005-12-31 | Skr46.24 Million | +2.49% |
| 2004-12-31 | Skr45.12 Million | +47.78% |
| 2003-12-31 | Skr30.53 Million | -58.57% |
| 2002-12-31 | Skr73.69 Million | -36.12% |
| 2001-12-31 | Skr115.35 Million | +35.89% |
| 2000-12-31 | Skr84.89 Million | -- |